Agilis Biotherapeutics Sponsors Research Session at International Ataxia Research Conference in Windsor, UK

Cambridge, MA, March 28, 2015--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Agilis sponsored the research poster sessions at The International Ataxia Research Conference 2015 that took place in Windsor, England on the 25th-28th of March. The conference was organized by Friedreich's Ataxia Research Alliance (FARA), which partnered with Ataxia UK, Ataxia Ireland and GoFAR to co-host what was the largest ataxia research conference ever convened. It was hailed as a great success for the advancement of ataxia research with new collaborations formed and ground breaking research being presented. Delegates arrived from all over the world to discuss the latest research in the ataxias. To read more about the conference see **http://curefa.org/conference.**

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's Ataxia, Angelman Syndrome and Fragile X Syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's Ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 people

living with Angelman Syndrome in the US. Fragile X Syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809